NEW YORK, Aug. 4 (GenomeWeb News) - Chemical genomics firm NeoGenesis Pharmaceuticals said today that it has signed a multi-year drug discovery collaboration agreement with Amgen.
NeoGenesis will use its ALIS (Automated Ligand Identification System) platform along with its compound libraries and lead optimization technologies in the project, which will focus on the discovery of small-molecule drugs for cancer, neurodegenerative diseases, and inflammatory diseases.
The company will receive research funding, milestone payments, and royalties based on the successful development of drug candidates.
NeoGenesis, headquartered in Cambridge, Mass., has similar partnerships with Aventis Pharma, Biogen, Celltech, Japan Tobacco, Merck, Mitsubishi Pharma, Pfizer, Schering-Plough, and Tularik.